Cargando…

Association of antibiotic exposure with the mortality in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy: A hospital-based retrospective cohort study

BACKGROUND: Preclinical studies showed that antibiotic exposure played a role in clinical outcomes in patients with chemotherapy via modulation of microbiota. However, it remains unknown whether antibiotic exposure during the bevacizumab therapy affects the clinical outcomes in metastatic colorectal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Linbin, Zhuang, Tingting, Shao, Erqian, Liu, Yanhong, He, Huimin, Shu, Zhimin, Huang, Yan, Yao, Yichen, Lin, Shan, Lin, Shaoqin, Chen, Xi, Chen, Xiong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6736303/ https://www.ncbi.nlm.nih.gov/pubmed/31504043 http://dx.doi.org/10.1371/journal.pone.0221964

Ejemplares similares

Fatal Adverse Events Associated With Programmed Cell Death Ligand 1 Inhibitors: A Systematic Review and Meta-Analysis
por: Wang, Xuewen, et al.
Publicado: (2020)

Effect and safety of bevacizumab-containing chemotherapy treatment in Chinese patients with metastatic colorectal cancer
por: Wu, Qian, et al.
Publicado: (2013)

Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy
por: Österlund, P, et al.
Publicado: (2011)

Gut Microbiota and Sunitinib-Induced Diarrhea in Metastatic Renal Cell Carcinoma: A Pilot Study
por: Su, Zhimin, et al.
Publicado: (2021)

Comprehensive molecular analysis to predict the efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer
por: LIM, SUNG HEE, et al.
Publicado: (2023)

Efficacy of bevacizumab-containing chemotherapy in metastatic colorectal cancer and CXCL5 expression: Six case reports
por: Novillo, Apolonia, et al.
Publicado: (2020)

FOLFOX‐bevacizumab chemotherapy in patients with metastatic neuroendocrine tumors
por: Lacombe, Caroline, et al.
Publicado: (2023)

Posterior Reversible Encephalopathy Syndrome after a Variety of Combined Chemotherapies Containing Bevacizumab for Metastatic Colon Cancer
por: Katada, Eiichi, et al.
Publicado: (2018)

Association between platelet count and hepatocellular carcinoma overall survival: a large retrospective cohort study
por: Lu, Linbin, et al.
Publicado: (2020)

Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer
por: Yamamoto, Shun, et al.
Publicado: (2021)

The impact of microsatellite instability status and sidedness of the primary tumor on the effect of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer
por: Kim, Seung Tae, et al.
Publicado: (2018)

The Impact of Bevacizumab and Chemotherapy on Quality of Life in Metastatic Colorectal Cancer Patients
por: Moisuc, Diana Cornelia, et al.
Publicado: (2023)

The Prognostic and Predictive Value of Carbohydrate Antigen 19-9 in Metastatic Colorectal Cancer Patients with First Line Bevacizumab Containing Chemotherapy
por: Jiang, Chang, et al.
Publicado: (2017)

Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer
por: Geva, Ravit, et al.
Publicado: (2013)

The Efficacy of Bevacizumab in Different Line Chemotherapy for Chinese Patients with Metastatic Colorectal Cancer
por: Yin, Chenxi, et al.
Publicado: (2016)

Chemotherapy plus Panitumumab Versus Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer: A Meta-analysis
por: Li, Zhigui, et al.
Publicado: (2018)

Elemene-containing hyperthermic intraperitoneal chemotherapy combined with chemotherapy for elderly patients with peritoneal metastatic advanced gastric cancer
por: Chen, Zhi-Xiong, et al.
Publicado: (2022)

Efficacy and safety of sintilimab plus bevacizumab in metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy: an open-label phase 2 study
por: Lu, Nian, et al.
Publicado: (2023)

Clinical outcomes with bevacizumab-containing and non-bevacizumab–containing regimens in patients with recurrent glioblastoma from US community practices
por: Chen, Clara, et al.
Publicado: (2015)

Pneumothorax as a Complication of Bevacizumab-Containing Chemotherapy: A Systematic Review of Case Reports
por: Rehman, Shafi, et al.
Publicado: (2022)

Bevacizumab Added to Neoadjuvant Chemotherapy in HER2-Negative Non-Metastatic Breast Cancer
por: Wan, Guoxing, et al.
Publicado: (2019)

Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer
por: Loupakis, Fotios, et al.
Publicado: (2018)

Trends in Use and Perceptions About Triplet Chemotherapy Plus Bevacizumab for Metastatic Colorectal Cancer
por: van Nassau, Sietske C., et al.
Publicado: (2021)

Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis
por: Sun, Zhengwu, et al.
Publicado: (2020)

Bevacizumab-containing regimens after cetuximab failure in Kras wild-type metastatic colorectal carcinoma
por: LAM, KA ON, et al.
Publicado: (2013)

Economic Evaluation of Adding Bevacizumab to Chemotherapy for Metastatic Colorectal Cancer (mCRC) Patients in Indonesia
por: Kristin, Erna, et al.
Publicado: (2021)

Efficacy of Adding Bevacizumab in the First-Line Chemotherapy of Metastatic Colorectal Cancer: Evidence from Seven Randomized Clinical Trials
por: Chen, Yan-xian, et al.
Publicado: (2014)

Neoadjuvant Bevacizumab plus Chemotherapy versus Chemotherapy Alone to Treat Non-Metastatic Breast Cancer: A Meta-Analysis of Randomised Controlled Trials
por: Cao, Li, et al.
Publicado: (2015)

The efficacy and safety of irinotecan ± bevacizumab compared with oxaliplatin ± bevacizumab for metastatic colorectal cancer: A meta-analysis
por: Dai, Jiali, et al.
Publicado: (2019)

First‐line therapy of bevacizumab plus chemotherapy versus cetuximab plus chemotherapy for metastatic colorectal cancer patients with mucinous adenocarcinoma or mucinous component
por: Zhou, Yu‐Wen, et al.
Publicado: (2021)

Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study
por: Lièvre, Astrid, et al.
Publicado: (2009)

Bevacizumab plus chemotherapy as third- or later-line therapy in patients with heavily treated metastatic colorectal cancer
por: Yang, Qiong, et al.
Publicado: (2015)

Bevacizumab plus chemotherapy in elderly patients with previously untreated metastatic colorectal cancer: single center experience
por: Ocvirk, Janja, et al.
Publicado: (2016)

Bevacizumab Combined with Chemotherapy Improves Survival for Patients with Metastatic Colorectal Cancer: Evidence from Meta Analysis
por: Ilic, Irena, et al.
Publicado: (2016)

Overweight is associated with better prognosis in metastatic colorectal cancer patients treated with bevacizumab plus FOLFOX chemotherapy
por: Cybulska-Stopa, Bożena, et al.
Publicado: (2020)

Prognostic value of blood-based fibrosis biomarkers in patients with metastatic colorectal cancer receiving chemotherapy and bevacizumab
por: Nissen, Neel I., et al.
Publicado: (2021)

Portal Vein Thrombosis in Metastatic Colorectal Cancer During FOLFIRI-bevacizumab Chemotherapy Successfully Treated with Apixaban
por: Fujiwara, Yu, et al.
Publicado: (2020)

Efficacy and safety of chemotherapy combined with bevacizumab in Chinese patients with metastatic colorectal cancer: A prospective, multicenter, observational, non-interventional phase IV trial
por: Wang, Fenghua, et al.
Publicado: (2021)

Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial
por: Guan, Zhong-Zhen, et al.
Publicado: (2011)

Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients
por: Abajo, A, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_0lhbo2lhqk3hscouvdotca1j17